González-Clemente José M, García-Castillo María, Gorgojo-Martínez Juan J, Jiménez Alberto, Llorente Ignacio, Matute Eduardo, Tejera Cristina, Izarra Aitziber, Lecube Albert
Endocrinology and Nutrition Service, Parc Taulí University Hospital, Institute for Research and Innovation Parc Taulí, Universitat Autònoma de Barcelona, Sabadell, Barcelona, Spain.
Biomedical Research Networking Center in Diabetes and Associated Metabolic Disorders (CIBERDEM), Carlos III Health Institute, Madrid, Spain.
Diabetes Ther. 2022 Jul;13(7):1281-1298. doi: 10.1007/s13300-022-01280-6. Epub 2022 Jun 10.
Dapagliflozin is a selective sodium-glucose cotransporter 2 inhibitor (SGLT2i) indicated for the treatment of type 2 diabetes mellitus (T2DM), heart failure with reduced ejection fraction and chronic kidney disease. In all indications, treatment can be initiated in adults with estimated glomerular filtration rate of at least 25 mL/min/1.73 m. As monotherapy or as an additive therapy, dapagliflozin has been shown to promote better glycaemic control, associated with a reduction in body weight and blood pressure in a wide range of patients. In addition, dapagliflozin has a positive impact on arterial stiffness, helps to control the lipid profile and contributes to a reduced risk of cardiovascular complications. This article reviews the current scientific evidence on the role of dapagliflozin in cardiovascular risk factors including arterial stiffness, cardiovascular disease and heart failure in patients with T2DM, with the aim of helping to translate this evidence into clinical practice. The underuse of SGLT2i in actual clinical practice is also discussed.
达格列净是一种选择性钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i），适用于治疗2型糖尿病（T2DM）、射血分数降低的心力衰竭和慢性肾脏病。在所有适应症中，估计肾小球滤过率至少为25 mL/min/1.73 m²的成人患者可开始治疗。作为单一疗法或附加疗法，达格列净已被证明能促进更好的血糖控制，在广泛的患者中与体重减轻和血压降低相关。此外，达格列净对动脉僵硬度有积极影响，有助于控制血脂谱，并有助于降低心血管并发症的风险。本文综述了关于达格列净在T2DM患者心血管危险因素（包括动脉僵硬度、心血管疾病和心力衰竭）中作用的当前科学证据，旨在帮助将这些证据转化为临床实践。还讨论了SGLT2i在实际临床实践中的使用不足情况。
